ACTG 076--ORAL ZIDOVUDINE IN PREGNANT HIV-INFECTED WOMEN AND THEIR INFANTS

ACTG 076--感染艾滋病毒的孕妇及其婴儿口服齐多夫定

• 批准号: 3766539
• 负责人: MARILYN G DOYLE
• 金额: --
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766539
• 关键词: AIDS education /prevention; AIDS therapy; HIV infections; antiAIDS agent; chemoprevention; clinical trials; communicable disease control; communicable disease transmission; congenital infection; drug screening /evaluation; female; human pregnant subject; human subject; human therapy evaluation; intravenous administration; microorganism disease chemotherapy; newborn human (0-6 weeks); oral administration; pediatric AIDS; perinatal; pregnancy; zidovudine

This is a multicenter study designed to determine whether the vertical transmission of HIV can be interrupted by continuous oral ZDV administration to HIV infected pregnant women beginning at 14 to 34 weeks of gestation, an intravenous intrapartum infusion, and oral ZDV administration to their infants from birth to six weeks of age. This study will also evaluate the safety of zidovudine for both the pregnant woman and the newborn infant.

这是一项多中心研究，旨在确定垂直 持续口服 ZDV 可阻断 HIV 传播 从 14 至 34 周开始对感染 HIV 的孕妇进行给药 妊娠期、产时静脉输注和口服 ZDV 给从出生到六周大的婴儿施用。 这 研究还将评估齐多夫定对孕妇的安全性 妇女和刚出生的婴儿。